Company ProfilePremium

BTC Health Limited

Company Profile Analysis

Ticker: BTC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
BTC Health Limited - Company showcase

Year Founded & Workforce

2000

BTC Health Limited logo

BTC Health Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

BTC Health Limited Overview

FieldDetail
Legal nameBTC Health Limited (styled "BTC health Limited" in some filings)
Former nameBiotech Capital Limited
ABN / ACNABN 45 091 979 172 / ACN 091 979 172
Incorporated14 March 2000 (per TradingView company profile; consistent with ACN series)
Incorporation jurisdictionAustralia (public company limited by shares, domiciled in Australia — FY2026 Annual Report, Note 1)
Legal / tax statusRegistered Pooled Development Fund under the Pooled Development Funds Act 1992 (Cth)
Accounting statusInvestment entity under AASB 10; investees held at fair value through profit or loss (Level 3)
Headquarters / registered officeLevel 1, 10 Oxley Road, Hawthorn VIC 3122, Australia
Previous office (data-provider records)Suite 201, 697 Burke Road, Camberwell VIC 3124
Exchange / tickerAustralian Securities Exchange, ASX: BTC (Yahoo/Reuters-style: BTC.AX)
ISINAU000000BTC7
Other identifiersFIGI BBG000C028N0; German WKN 552817
CUSIPNot applicable / not publicly disclosed (Australian security)
Fiscal year end30 June
Ordinary shares on issue357,454,456 (30 June 2026 and 14 August 2026)
Unlisted options21,000,000
Shareholders981 holders (14 August 2026)
AuditorRSM Australia Partners (Melbourne), lead partner A L Whittingham. Appointed at the 28 November 2025 AGM after a competitive tender, replacing Grant Thornton Audit Pty Ltd.
Share registryLink Market Services Limited, Melbourne
EmployeesNot publicly disclosed in the annual report. Third-party directory lists 11–50 employees across the group (annualreports.co.uk).
Market capitalisationApprox. A$20–21 million. Based on a last observed share price of A$0.057–0.060 (InvestSMART, August 2026) × 357.45m shares. The live price as at 9 October 2026 should be verified.
Websitewww.btchealth.com.au
Executive Chairman & Managing DirectorDr Richard Treagus
CFO & Company SecretarySalesh Balak
Chief Operating OfficerJoshua Kahanovitz

No change of listing or ticker has occurred.

MetricFY2024FY2025FY2026
Group employees (number)———

Not publicly disclosed. The annual report does not state a headcount. The KMP disclosure covers 5 individuals (3 directors, CFO and COO).

BTC Health is a micro-cap, Melbourne-based specialty medical-products distribution group wrapped inside a tax-advantaged Pooled Development Fund structure. Through three wholly owned investee companies — BTC Cardio, BTC Speciality Health and BTC Pharma — it in-licenses and distributes imported medical devices, consumables and specialty pharmaceuticals into Australian and New Zealand public and private hospitals. Its focus areas are cardiothoracic surgery, ECMO/critical care, post-operative pain, neuro-spinal procedures and respiratory medicine.

Group revenue was A$10.27m in FY2026 (unaudited). Since 2024 the business has pivoted decisively towards cardiac and critical care, anchored by the January 2025 takeover of Corcym's ANZ heart-valve business. Cardio now represents 57% of revenue. The group is near break-even at EBITDA level, debt-free, and dependent on exclusive supplier agreements and hospital procurement cycles.

Its investment case rests on four things: converting a large ECMO evaluation pipeline, rebuilding infusion-pump volumes, managing supply risk from a now-insolvent pharmaceutical manufacturer, and the PDF's tax-free capital-gains treatment for shareholders.


The company's own description

The FY2026 Annual Report and every recent ASX release use the same self-description. BTC Health describes itself as a Pooled Development Fund that actively invests in businesses which acquire, develop and distribute innovative medical products in Australia and New Zealand. It says it is building a group of high-growth businesses that together give access to some of the best specialised therapeutics and medical devices from around the world.

The FY2026 Directors' Report states its principal activity as follows: the company is a PDF registered under the PDF Act 1992 and invests in entities in the healthcare sector. It held direct interests in three investee companies at 30 June 2026 and continues to seek investment opportunities in healthcare.

The FY26 Investor Presentation adds the PDF rationale. PDFs exist to increase the supply of capital to SMEs. PDFs are taxed at 15% on income and gains from SME equity investments. Shareholders are exempt from tax on income and gains from holding and disposing of PDF shares.

Independent characterisation

Stripped of the PDF wrapper, BTC Health is an asset-light, exclusive-agency medical device and specialty pharmaceutical distributor for the ANZ market. Its key characteristics are:

  1. No proprietary manufacturing and no meaningful R&D. Products are sourced from overseas or domestic manufacturers under exclusive or semi-exclusive distribution agreements. Examples include Corcym (Italy/UK), Eurosets (Italy), Exstent (UK), Micrel (Greece), IZI Medical (USA), Ilumark (Germany), Morpheus AG, Andocor NV (Belgium), SmartCanula LLC, Jafron Biomedical (China/HK) and Arna Pharma (Sydney).

  2. Value-add is regulatory and commercial. BTC acts as Australian sponsor (TGA registration, ARTG listings and pharmacovigilance). It manages reimbursement — Prescribed List of Medical Devices for devices and the PBS for Bronchitol. It also handles hospital tendering, clinical evaluations, field clinical support, inventory holding and logistics.

  3. The customer base is concentrated in hospitals. This means State public hospital systems (via purchase orders and tenders), private hospitals and specialist clinicians: cardiothoracic surgeons, perfusionists, intensivists, anaesthetists, interventional radiologists and respiratory physicians.

  4. The model has three layers. The listed parent is a holding vehicle that funds working capital via interest-free loans (A$1.90m outstanding to BTC Cardio at 30 June 2026). The investees carry the operating P&L. Value is recognised at the parent through directors' DCF valuations.

Revenue model

Revenue typeShare of group revenueComment
Product sales — implantable / single-use medical devicesMajority (Cardio 57% plus Neurospinal 13% in FY2026)Heart valves, PEARS implants, cannulas, biopsy needles, markers, bone removal devices
Product sales — capital equipmentIncluded in Cardio (ECMO A$1.60m in FY2026)Eurosets ECMO consoles and systems; lumpy, tender-driven
Product sales — consumables / disposablesIncluded in Infusion Pumps (19%) and CardioElastomeric and electronic pump disposables, oxygenators, circuits
Specialty pharmaceuticals11% (FY2026)Bronchitol (PBS-listed) and Aridol
Royalty incomeImmaterial / not separately disclosedSingle-digit royalty from Arna Pharma on Singapore/Malaysia sales for 3 years from February 2025 (now at risk given Arna's administration)
Services, subscription, licensing-outNil disclosed—
Statutory parent revenueInterest income only: A$29,419 in FY2026Parent records no product revenue

Value-chain position

BTC sits in the downstream commercialisation and distribution layer:

Manufacturer (offshore OEM) → [BTC: in-licensing, regulatory sponsorship, reimbursement listing, importation, warehousing, sales/clinical support] → Hospital procurement (State health purchasing bodies / private hospital groups) → Clinician / patient

Customer types and end-markets

Customer typeEnd-market / clinical areaInvestee
Public tertiary hospitals (cardiothoracic units, ICUs, paediatric hospitals)Cardiac surgery, ECMO / extracorporeal life support, critical care, hemoperfusionBTC Cardio
Private hospitalsCardiac surgery (valves, PEARS), post-operative painBTC Cardio, BTC Speciality Health
Surgical / anaesthesia departmentsPost-operative pain management (elastomeric and electronic ambulatory infusion pumps)BTC Speciality Health
Interventional radiology / spineTissue biopsy, image-guided surgery markers, bone removalBTC Speciality Health
Respiratory physicians, cystic fibrosis clinics, lung function labs; community and hospital pharmacyCystic fibrosis therapy (Bronchitol); bronchial challenge testing (Aridol)BTC Pharma

Geography: Australia and New Zealand only (FY2026 Annual Report, Note 3 — single segment, single geography: Australia).

Strategy

Stated strategy — recurring themes

The themes below are drawn from the FY2026 AR, the FY26 Investor Presentation and the November 2025 AGM address.

  1. Mission statement: "Improving patients' lives through global medical innovation" (presentation tagline).

  2. Build a diversified specialty medical products group. The AGM 2025 address describes reshaping the business into a more diversified medical products company that is less dependent on a single product line.

  3. Strengthen the core business (FY26 Strategy slide):

    • reset the cost base

    • improve margins in core businesses

    • prioritise cash flow and balance-sheet strength

    • diversified growth

  4. Diversification as resilience. The FY26 presentation states that no single product line represents more than a quarter of group revenue. This claim is consistent at product-line level; Corcym valves at A$2.34m are about 23%.

  5. Ongoing strategic review of investments to ensure they generate sustainable cash flows and profitability (FY2026 Directors' Report).

  6. Continued search for new healthcare investments in technologies and companies that would benefit from management expertise and development capital.

FY2027 priorities (FY2026 AR and FY26 Update)

#PriorityMeasurable indicator to watch
1Convert the advanced ECMO evaluation pipeline into State public hospital contractsECMO revenue (FY2026 A$1.60m vs FY2025 A$2.29m); new contract announcements
2Increase Perceval Plus heart-valve utilisation in established centresCorcym revenue growth on A$2.34m base
3Complete conversion of infusion pump users to Micrel and Elasto-QPump revenue stabilising above A$1.92m
4Expand the neurospinal customer base and add new pharmaceutical products to BTC PharmaNeurospinal revenue (A$1.39m); new pharma in-licensing, now urgent given Arna
5Hold the reset cost base (about A$4.2m) while revenue scalesOpex / sales below 41%

Board objective: Build on FY2026's positive EBITDA toward sustainable profitability.

Initiatives announced in the last 24 months (Oct 2024 – Oct 2026)

DateInitiativeTypeStatus
1 Nov 2024Micrel and Elasto-Q listed on the Prescribed ListReimbursement / product transitionDone; conversion ongoing
Dec 2024Corcym ANZ heart-valve business assumed (effective 1 Jan 2025)Business acquisition / partnershipIntegrated
H1 FY2025RCH Melbourne 5-year A$5m ECMO contractContractExecuting
Feb 2025Arna Pharma licence made indefinite; ROFR on Arna pipeline; SG/MY rights monetised via royaltyPartnershipImpaired by Arna administration (Sep 2026)
Mar 2025New CFO / Company Secretary and COO appointmentsLeadershipDone
Jul 2025Adelaide WCH ECMO order (A$0.5m)ContractInstalled Jul 2025
FY2026Andocor CPB cannulas launchedNew product lineA$0.73m first-year revenue
FY2026SmartCanula exclusive ANZ agreementPartnershipRamping in FY2027
Nov–Dec 2025A$1.96m placement to professional and sophisticated investorsCapitalCompleted 2 Dec 2025
FY2026In-sourcing of company secretarial and tax workCost programmeAccounting/secretarial costs fell from A$88k to A$3k
13 Feb 2026Jafron Biomedical hemoperfusion exclusive ANZ distributionPartnershipRamping in FY2027
Nov 2025Auditor change to RSM after tenderGovernanceDone
Sep 2026Engagement with Arna administrators, TGA and Department of Health on continuity of supplyCrisis managementOngoing

ESG and sustainability commitments

No quantified ESG commitments are disclosed. Climate risk is acknowledged qualitatively in the risk section.

Medium-term targets and guidance

TargetSourceOutcome
FY2025: positive EBITDA and clear pathway to sustainable profitHY25 UpdateGroup EBITDA A$3k (technically positive); adjusted A$0.18m
FY2026: double-digit revenue growthAGM 2025, HY26 presentationMissed (+0.4%)
FY2027: no numeric guidance; qualitative objective to build on positive EBITDA toward sustainable profitabilityFY2026 AR—
FY2027 Pharma: Bronchitol/Aridol sales up to A$0.5m without further supply (vs A$1.1m in FY2026)ASX 8 Sep 2026Negative guidance revision

Products & Services

Pricing is not publicly disclosed for any product. Reimbursement status is noted where disclosed.

BTC Cardio — Cardiothoracic & Critical Care (57% of FY2026 revenue)

Product / brandSupplier (country)Description and capabilitiesTarget customerYear / statusCommercial notes
Corcym heart valves, incl. Perceval PlusCorcym Srl (Italy/UK; formerly LivaNova's heart-valve business)Surgical aortic heart valve portfolio. Perceval Plus is a sutureless, self-anchoring bioprosthetic aortic valve that reduces cross-clamp time. The full ANZ valve range distributed is not itemised in filings.Cardiothoracic surgeons; public and private cardiac centresBTC responsibility from 1 Jan 2025FY2026 revenue A$2.34m (+91%). FY27 priority is higher Perceval Plus utilisation in established centres.
Eurosets ECMO / ECLS systems (ECMOLIFE, COLIBRI, Landing Advance, ECLS heater-coolers, oxygenators incl. NEOLA)Eurosets Srl (Italy)Extracorporeal membrane oxygenation consoles, circuits and oxygenators for adult, paediatric and neonatal life support; heater-cooler units. Landing Advance received TGA approval on 1 May 2024.ICUs, paediatric hospitals, perfusion departmentsExclusive ANZ since Dec 2023FY2026 revenue A$1.60m (FY2025 A$2.29m). RCH Melbourne A$5m / 5-year contract; Adelaide WCH A$0.5m order (Jul 2025). Evaluations "well advanced across most major public hospitals".
PEARS (Personalised External Aortic Root Support, "ExoVasc")Exstent Ltd (UK)Custom-made mesh sleeve manufactured from patient CT imaging to support a dilated aortic root (e.g. Marfan syndrome) without replacing itCardiothoracic surgeonsExclusive ANZ since Apr 2024FY2026 revenue A$1.10m (+20%)
Cardiopulmonary bypass (CPB) cannulasAndocor NV (Belgium)Arterial and venous cannulas for connecting patients to the heart-lung machinePerfusionists, cardiac surgeonsIntroduced FY2026First-year revenue A$0.73m
SmartCanula venous cannulasSmartCanula LLCSelf-expanding venous drainage cannulas for CPB and ECMOPerfusion, cardiac surgery, ECMO teamsExclusive ANZ, signed FY2026Not material to FY2026 revenue; expected to build through FY27
Jafron hemoperfusion cartridges (HA-series and related)Jafron Biomedical (HK) Co Ltd (China)Sorbent hemoperfusion cartridges for blood purification in sepsis, cytokine storm, liver failure and critical care, used with CRRT/ECMO circuitsICUs, nephrology / critical careExclusive ANZ, announced 13 Feb 2026Not material to FY2026 revenue; requires market development
LPS Adsorber (endotoxin adsorber)Not confirmed in filings (listed in Morningstar product description)Extracorporeal endotoxin removalICU——
Cardiothoracic surgical instrumentsWexler (exclusive agreement 15 May 2024) — product scope inferredSurgical instruments for cardiothoracic procedures (FY2026 AR lists "cardiothoracic surgical instruments" in BTC Cardio portfolio)Cardiothoracic theatresSince 2024Revenue not separately disclosed

BTC Speciality Health — Post-Operative Pain (19% of FY2026 revenue)

Product / brandSupplierDescriptionTarget customerYear / statusCommercial notes
ambIT electronic ambulatory infusion pumpsFormerly via Admedus Infusion heritageProgrammable ambulatory pumps for post-operative regional anaesthesia / painAnaesthetists, surgical wardsDiscontinuedPreviously dominated group revenue; user base being converted. Its exit is the main reason for the FY2023 write-down and FY2025–26 pump revenue decline.
Micrel ("Rythmic" / Rhythm Evolution) electronic infusion pumpsMicrel Medical Devices (Greece)Ambulatory electronic infusion pumps for pain management and other therapiesAnaesthetists, acute pain servicesOn Prescribed List since 1 Nov 2024Conversion of ambIT users ongoing
Elasto-Q elastomeric pumpsNot named in filingsDisposable, non-electronic elastomeric infusion pumps for continuous local anaesthetic deliverySurgeons, anaesthetistsOn Prescribed List since 1 Nov 2024Conversion ongoing
Infusion and nerve catheter kits; TIVA productsVariousConsumable kits for regional nerve blocks; total intravenous anaesthesia accessoriesAnaesthesia departmentsOngoingRevenue not separately disclosed

Total infusion pump revenue was A$1.92m in FY2026, down 35% from about A$2.95m.

BTC Speciality Health — Neuro-Spinal / Interventional (13% of FY2026 revenue)

Product / brandSupplierDescriptionTarget customerYear / statusCommercial notes
IZI Medical biopsy needles, incl. Bonopty coaxial bone biopsy systemIZI Medical Products (USA)Single-use tissue and bone biopsy, interventional radiology productsInterventional radiologists, spine surgeonsExclusive ANZ (announcement drove a 27% share-price jump)Part of A$1.39m neurospinal revenue
Ilumark radiological / navigation markersIlumark GmbH (Germany; wholly owned by IZI)Single-use reflective markers for image-guided surgical navigationNeurosurgery, orthopaedic and spine theatresExclusive ANZPart of A$1.39m
Rebellion bone removal systemMorpheus AGBone cutting / removal device for spine and cranial surgerySpine and neurosurgeonsExclusive ANZ since Dec 2023Part of A$1.39m
TeDan productsTeDan Surgical Innovations (agreement 5 Jun 2024)Scope not detailed in sources reviewed (TeDan is a surgical retractor specialist; mapping to neuro-spinal is inferred)SurgeonsSince 2024—

Neurospinal revenue was A$1.39m in FY2026 (down 9%). The FY27 priority is expanding the customer base.

BTC Pharma — Specialty Pharmaceuticals (11% of FY2026 revenue)

ProductManufacturer / licensorDescriptionTarget customerRegulatory / reimbursementCommercial notes
Bronchitol (mannitol 40mg inhalation powder, hard capsule; AUST R 168002)Arna Pharma Pty Ltd (Sydney; ex-Pharmaxis)Inhaled osmotic agent that improves mucus clearance in cystic fibrosisCF clinics, respiratory physicians, pharmaciesTGA-registered; PBS-listed; BTC Pharma is sponsorFY2026 revenue declined on competitive pressure. TGA anticipated shortage from 1 Apr 2027. About 8 months of stock held at 8 Sep 2026.
Aridol (mannitol bronchial challenge test, composite pack; AUST R 116832)Arna PharmaInhaled diagnostic test for bronchial hyper-responsiveness (asthma diagnosis)Lung function laboratories, respiratory physiciansTGA-registered; BTC Pharma is sponsorLess than 1 month of stock at 8 Sep 2026. TGA anticipated shortage from 1 Oct 2026.

Combined Bronchitol + Aridol revenue was A$1.10m in FY2026 (FY2025 A$1.26m). BTC Pharma was the most profitable investee, with EBITDA of A$0.36m. After the Arna administration, the company guides to FY2027 sales of up to A$0.5m if supply does not resume.

Financial Narrative

Because of the investment-entity structure, this section presents two parallel financial sets:

6A — Group (unaudited, look-through operating business): Source: FY26 Investor Presentation, slide 9, and FY26 / HY26 Updates.

6B — Statutory parent (audited): Source: FY2026 Annual Report, including its 5-year remuneration-report table, and prior filings.

6A. Group operating performance (unaudited, consolidated non-statutory)

Table 6A.1 — Income statement metrics: notes and sources

Notes: FY2025 and FY2026 are exact disclosed figures (FY2025: revenue A$10,232,894, EBITDA A$2,770; FY2026: revenue A$10,271,312, EBITDA A$137,721). FY2022–FY2024 are read from presentation charts, which are rounded. Group operating income (EBIT), pre-tax income and net income on a consolidated basis are not publicly disclosed.

Table 6A.3 — Half-yearly progression

Notes: H2 figures are derived as full year less H1. H2 FY2026 revenue of A$5.29m is confirmed in the FY26 Investor Presentation. H2 FY2025 is fully derived.

Group revenue CAGR FY2022–FY2026: about 7.5% per year (A$7.7m to A$10.27m over 4 years). The FY2022–FY2024 CAGR was about 3.2%. The FY2024–FY2026 CAGR was about 11.9%, driven almost entirely by the Corcym acquisition.

Commentary — Group P&L

Revenue. Three distinct phases are visible:

  1. FY2022–FY2024 stagnation (A$7.7m to A$8.2m). The ambIT pump business was mature and then discontinued.

  2. FY2025 step-up (+25% to A$10.23m). This came from a half-year of Corcym heart valves, ECMO capital sales (A$2.29m) and PEARS.

  3. FY2026 plateau (A$10.27m, +0.4%). A full year of Corcym (+91%) and new cannulas (A$0.73m) were almost exactly offset by declines in pumps (−35%), ECMO (−30%), pharma (−13%) and neurospinal (−9%).

Management explicitly missed its double-digit revenue growth target. It attributed the miss to State public hospital purchase-order timing on ECMO.

Gross margin. Margin has been range-bound at 40–45%. The FY2024 peak of 45% likely reflects ambIT inventory sell-through at full margin (the FY2023 4E flagged remaining ambIT stock to be sold). FY2025–26 at about 42% reflects a mix shift to heart valves and capital equipment, where distribution margins are typically thinner than on proprietary-like consumables. This is an analyst inference; product-level margins are not disclosed.

Operating expenses. Opex rose from A$3.9m to A$4.3m in FY2025 with Corcym integration and the cardio sales force, then fell 2% to A$4.23m in FY2026. The decline came from bringing company secretarial and tax work in-house and from other cost actions. Operating leverage is now the central thesis: opex is about 41% of sales against a gross margin of about 42.5%, so each incremental A$1m of revenue at constant margin would add roughly A$0.4m of EBITDA if the cost base is held.

EBITDA. Group EBITDA improved from −A$0.7m (FY2023) to +A$0.14m (FY2026). It remains thin (1.3% margin) and highly sensitive to ECMO order timing. H2 FY2026 EBITDA of A$0.24m is the best half in the five-year series.

6B. Statutory parent financials (audited)

Table 6B.4 — Statutory balance sheet (AUD)

Notes: - FY2022 and FY2023 cash are derived from FY2024 closing cash (A$2,022,155) and change-in-cash data from aggregators (FY2024 +A$0.29m, FY2023 −A$0.43m). They are approximate.

  • FY2024 investments are the FY2025 opening balance.

  • Goodwill and intangibles at investee level are not disclosed. Licence values are embedded in the fair value of investments, e.g. BTC Pharma's value reflects the Arna licence.

  • The A$141,348 insurance premium funding facility drawn in August 2025 was fully repaid within FY2026.

Table 6B.5 — Group cash (look-through, unaudited)

FY2024 group cash is not disclosed in the documents reviewed.

Table 6B.6 — Statutory cash flow (AUD)

Notes: FY2022–FY2024 OCF are from stoxray/InvestSMART aggregators and are consistent with InvestSMART's −A$0.4m to −A$0.43m. FY2025–FY2026 are audited. Group-level (consolidated) OCF, capex and FCF are not publicly disclosed.

Table 6B.7 — Ratios

Notes: ROIC, interest coverage, asset turnover and cash conversion cycle are not meaningful or not disclosed. The group carries no debt (interest expense was only A$4,993 on a premium funding facility in FY2026). Consolidated balance sheets, inventory, receivables and payables of investees are not published. Net debt / EBITDA is not meaningful because the company has net cash.

Commentary — Statutory accounts

Earnings quality. Statutory earnings are almost entirely a function of directors' Level 3 DCF valuations:

  • FY2023's A$9.62m write-down produced a A$10.17m loss.

  • FY2025's A$4.65m uplift (post-Corcym) produced a A$3.98m profit.

  • FY2026's A$0.43m net gain produced a A$34,728 profit.

These movements are non-cash. The parent's underlying cash burn is a steady A$0.35–0.50m per year, partly offset by interest income. Investors should anchor on group EBITDA and cash, not statutory EPS.

FY2026 valuation dynamics. Total investment value rose 5.7% to A$7.99m, but the mix shifted sharply:

The discount rates used were 20.0–21.33% pre-tax and 15–16% post-tax, applying a 5% growth rate on licensed products only, with pipeline products excluded.

Balance sheet. The balance sheet is clean: no debt, A$1.47m parent cash and A$11.2m net assets (3.14c NTA per share). However:

  • About 70% of total assets are Level 3 unlisted valuations and 17% are interest-free, on-demand loans to BTC Cardio.

  • RSM flagged both investment valuation and going concern as Key Audit Matters for FY2026. Going concern was supported by cash-flow forecasts to August 2027.

  • There are A$30.1m of unrecognised carried-forward tax losses (A$29.2m revenue, A$0.9m capital). These do not expire, but their utility is limited by PDF tax rules and profit generation.

Equity history. Issued capital is A$58.56m against accumulated losses of A$48.10m. Over its life, the company has consumed most of the capital raised.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityOwnershipIncorporationRole

BTC Health Limited

Listed parent (PDF)

Australia

Holding company, capital allocator, funds investee working capital

BTC Cardio Pty Ltd

100%

Australia

Cardiology, cardiothoracic and critical care products (Corcym, Eurosets, PEARS, cannulas, SmartCanula, Jafron)

BTC Speciality Health Pty Ltd

100%

Australia

Distributor of medical devices, consumables and specialty pharmaceuticals to ANZ hospitals. Two product lines: post-operative pain (infusion pumps) and neuro-spinal.

BTC Pharma Pty Ltd (formerly BioImpact)

100%

Australia

Licenses specialty pharmaceuticals (Bronchitol, Aridol). Can sublicense to BTC Speciality Health. TGA sponsor.

Revenue by Segment

Segment (AUD Mn)FY2024FY2025FY2026

Cardio revenue

—4.485.86

Infusion Pumps revenue

—2.951.92

Neurospinal revenue

—1.531.39

Pharma revenue

—1.261.10

Group total revenue

8.210.2310.27

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment share (%)

Segment share (%)FY2025FY2026

Cardio

4457

Infusion Pumps

2919

Neurospinal

1513

Pharma

1211

Segment Overview

SegmentYoY growth (%)

Cardio

31

Infusion Pumps

-35

Neurospinal

-9

Pharma

-13

Group

0.4

Investee revenue (AUD Mn)

Investee revenue (AUD Mn)FY2025FY2026

BTC Cardio revenue

4.485.86

BTC Speciality Health revenue

4.493.31

BTC Pharma revenue

1.261.10

Segment EBITDA (AUD Mn)

Segment EBITDA (AUD Mn)FY2022FY2023FY2024FY2025FY2026

BTC Cardio EBITDA

———-0.070.17

BTC Pharma EBITDA

————0.36

Total investee companies EBITDA

0.2-0.10.50.50.5

Group EBITDA (after parent costs)

-0.5-0.7-0.20.00.14

Revenue by Segment (FY2025–FY2026)

Cardio sub-line (AUD Mn)FY2025FY2026

Corcym heart valves

1.232.34

Eurosets ECMO

2.291.60

PEARS aortic root support

0.921.10

CPB cannulas (Andocor)

00.73

Income Statement

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Group revenue

7.77.88.210.2310.27

Cost of sales

———5.915.91

Gross profit

3.33.13.64.324.36

Operating expenses

3.83.83.94.324.23

Group EBITDA

-0.5-0.7-0.20.0030.14

Adjusted EBITDA (ex non-recurring)

———0.180.27

Non-recurring items

———0.180.13

Investee companies EBITDA

0.2-0.10.50.50.5

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

43404542.242.5

Operating cost ratio (opex / revenue)

49.448.747.642.241.1

EBITDA margin

-6.5-9.0-2.40.031.3

Adjusted EBITDA margin

———1.82.6

Income Statement (Half-Yearly)

Metric (AUD Mn)H1 FY2025H2 FY2025H1 FY2026H2 FY2026

Group revenue

5.344.894.985.29

Group EBITDA

0.26-0.26-0.100.24

Adjusted EBITDA

0.33-0.15-0.010.27

Income Statement (AUD)

Metric (AUD)FY2022FY2023FY2024FY2025FY2026

Revenue and other income (interest)

95,00413,26016,3609,96029,419

Investment fair value adjustment

0-9,619,8901,714,8094,646,820433,135

Total expenses (ex FV)

———675,482427,826

Net profit / (loss) after tax

-576,076-10,167,8621,055,2873,981,29834,728

Income tax expense

00000

Per share

Per shareFY2022FY2023FY2024FY2025FY2026

Basic EPS (cents)

-0.20-3.610.331.230.01

Diluted EPS (cents)

———1.180.01

Dividends per share (cents)

00000

NTA per share (cents)

———2.813.14

Share price at year end (AUD)

0.0400.0260.0380.0600.055

Expense line (AUD)

Expense line (AUD)FY2025FY2026

Executive director fees

40,00040,000

Non-executive director fees

80,00080,000

Accounting and company secretarial

88,3692,625

Legal fees

2,1990

Share-based payments

171,50866,092

Audit fees

121,800102,250

Insurance

82,54662,001

Interest expense

04,993

Other expenses

89,06069,865

Balance Sheet (AUD)

Metric (AUD)FY2022FY2023FY2024FY2025FY2026

Cash and cash equivalents

2,160,0001,730,0002,022,155620,1091,474,885

Investments at fair value (Level 3)

——2,914,8097,561,6297,994,764

Loans to investee companies

———1,158,6681,900,000

Total assets

———9,358,41511,385,074

Total liabilities

———201,950177,801

Total debt

00000

Net debt (negative = net cash)

-2,160,000-1,730,000-2,022,155-620,109-1,474,885

Net assets / equity

12,861,9642,779,9304,944,8599,156,46511,207,273

Goodwill and intangibles

00000

Working capital (current assets less current liabilities)

———436,1681,312,509

Key Financials

Metric (AUD Mn)FY2022FY2023FY2025FY2026

Group cash (BTC plus investees)

2.42.11.292.08

Cash Flow (AUD)

Metric (AUD)FY2022FY2023FY2024FY2025FY2026

Operating cash flow

-392,911-433,608-404,757-499,981-353,880

Capex

00000

Free cash flow (OCF less capex)

-392,911-433,608-404,757-499,981-353,880

Loans advanced to investees

———-960,865-741,332

Net proceeds from share issues / option exercises

———58,8001,949,988

Dividends paid

00000

Share buybacks

00000

Net change in cash

-198,480-433,590290,000-1,402,046854,776

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

Statutory ROE on closing equity (%)

-4.5-365.821.343.50.3

Statutory ROE on average equity (%)

—-130.027.356.50.3

Statutory ROA on closing assets (%)

———42.50.3

Current ratio (x)

———3.168.38

Debt / equity (x)

00000

Financial Analysis

InvesteeFY2025 value (AUD)FY2026 value (AUD)Change (AUD)Driver

BTC Cardio

1,165,4313,458,246

+2.29m

Full year of Corcym, PEARS and cannula growth

BTC Speciality Health

4,277,2813,001,810

−1.28m

Weaker Elasto-Q/Micrel uptake replacing ambIT

BTC Pharma

2,118,9171,534,708

−0.58m

Bronchitol competitive pressure

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY2024FY2025FY2026

Australia and New Zealand (group, unaudited)

8.210.2310.27

Rest of world

000

Operating Areas

AreaDirectionReason

Cardiac surgery (valves, PEARS, cannulas)

Fastest growing (+31% Cardio)

Corcym full year; new Andocor cannulas; PEARS adoption

ECMO capital equipment

Declining in FY2026 (−30%)

State public hospital purchase-order timing; evaluations completed but not converted

Post-operative pain (pumps)

Declining (−35%)

Planned exit of ambIT; slower-than-hoped conversion to Micrel/Elasto-Q

Respiratory pharma

Declining (−13%), with acute FY2027 risk

Competitive pressure on Bronchitol; manufacturer insolvency

Neuro-spinal

Declining (−9%)

Mature, established products; customer base not expanding

Valuation Snapshot

MetricValueSource / note

Latest observed share price

A$0.057–0.060

InvestSMART after the 20 Aug 2026 release.

Shares on issue

357,454,456

FY2026 AR

Market capitalisation

About A$20.4m at A$0.057; about A$21.4m at A$0.060

Calculated

52-week range (to Feb 2026)

A$0.051 – A$0.070

StockLight

Average daily volume

About 175,000 shares (historical)

InvestSMART / MarketIndex

Analyst coverage

None. No major broker covers BTC.

MarketIndex

Share price (AUD)

Share price (AUD)FY2022FY2023FY2024FY2025FY2026

Year-end share price

0.0400.0260.0380.0600.055

Share Price History

PeriodStart price (approx., AUD)End price (approx., AUD)Change (approx.)

1-year (Oct 2025 – Oct 2026)

0.0610.057−7%

3-year (Oct 2023 – Oct 2026)

about 0.06 (52-week high of 0.07 on 13 Nov 2023)

0.057

about −5%

5-year (Oct 2021 – Oct 2026)

about 0.085 (Nov 2021 NTA-release prices)

0.057

about −33%

Fiscal-year basis (30 Jun 2023 – 30 Jun 2026)

0.0260.055+112%

Valuation Multiples

MultipleBTC HealthBasis

Price / earnings (statutory)

About 590x

Not meaningful; FY2026 EPS 0.01c

Price / book (statutory NAV)

1.82x

A$20.4m / A$11.21m

Price / NTA

1.82x

5.7c / 3.14c

EV / Sales (group; EV = market cap less group cash of A$2.08m)

1.8x

A$18.3m / A$10.27m

EV / EBITDA (group adjusted)

About 68x

A$18.3m / A$0.27m

EV / EBITDA (group reported)

About 131x

A$18.3m / A$0.14m

Capital Markets

ItemStatus

Dividend history

Last dividends paid in May 2011, Jul 2011 and Nov 2012. No dividends paid, recommended or declared in FY2025 or FY2026. No DRP.

Dividend policy

None stated. Accumulated losses of A$48.1m.

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

No debt. A A$141,348 premium funding facility (Aug 2025) was fully repaid.

DPS (AUD cents)

DPS (AUD cents)FY2022FY2023FY2024FY2025FY2026

Dividends per share

00000

Share Price & Returns

DateActionSharesPrice (AUD)Proceeds

FY2025

Option exercises

1,200,0000.049

A$58,800

2 Dec 2025

Placement

32,131,1480.061

A$1.96m gross; A$1.95m net

Pending

Possible royalty-share issues to GLK / Kingfisher / Tau (related parties)

Determined at 30-day VWAP less 10%

—

A$187,549 royalties accrued; election deferred to 30 Jun 2027

Analyst Conclusions

Management guidance

There is no quantitative revenue or EBITDA guidance for FY2027. Management's qualitative objective is to build on positive EBITDA toward sustainable profitability, through five priorities:

  1. ECMO conversion

  2. Perceval Plus utilisation

  3. Pump conversion

  4. Neurospinal expansion and new pharma products

  5. Holding the cost base

Explicit negative guidance (8 September 2026): Bronchitol/Aridol sales of up to A$0.5m in FY2027 without further supply, versus A$1.1m in FY2026.

Consensus

None. There is no sell-side coverage, so no consensus growth expectations exist.

Illustrative FY2027 bridge (analyst framework, not a forecast)

DriverIndicative revenue impact vs FY2026 (AUD Mn)
Pharma (Arna supply interruption)Down by up to 0.6
ECMO recovery to FY2025 levelUp by up to 0.7
Corcym utilisation growthPositive, unquantified
New agencies (SmartCanula, Andocor full year, Jafron)Positive, unquantified
Pump conversionStabilisation to modest recovery

Net effect: On this framework, holding FY2026 group revenue of about A$10.3m depends on cardio execution offsetting the pharma loss. EBITDA is at risk because the lost revenue is BTC Pharma's, the group's highest-margin and most profitable investee.

Bull case

  1. Operating leverage on a reset cost base. Opex is A$4.23m (41.1% of sales) and gross margin 42.5%. H2 FY2026 already delivered A$0.24m EBITDA on A$5.29m revenue. Annualising the H2 run-rate plus ECMO recovery and new agencies could plausibly lift group EBITDA towards A$0.5–1.0m. On that basis, an EV of about A$18m would look inexpensive for a debt-free, tax-advantaged vehicle.

  2. Cardio is a credible growth franchise. Revenue rose from A$4.48m to A$5.86m (+31%), and BTC Cardio swung from −A$0.07m to +A$0.17m EBITDA. Three new agencies sell into the same customers, and the RCH contract provides a multi-year base.

  3. Asset backing plus tax shelter. NTA is 3.14c per share, there is no debt and there are A$30.1m of tax losses. Shareholder-level PDF tax exemption on gains provides downside support and appeal to concentrated, patient holders (NAOS 23.8%; insiders about 21%).

Bear case

  1. The most profitable unit is impaired. BTC Pharma contributed A$0.36m EBITDA — more than the whole group's A$0.14m reported EBITDA. Its sole manufacturer is in administration, and TGA shortages are anticipated from October 2026 (Aridol) and April 2027 (Bronchitol). Absent a supply solution, FY2027 group EBITDA could fall back to a loss, and the Pharma carrying value (A$1.53m) faces write-down.

  2. Growth has repeatedly disappointed. The FY2026 double-digit target was missed. ECMO conversion has slipped for at least two halves. Pumps fell 35%. The FY2022–FY2024 revenue CAGR was only about 3%. Statutory profits have depended on directors' Level 3 valuations, and the auditor flagged both valuation and going concern as Key Audit Matters.

  3. Structural fragility and governance. The group is sub-scale (A$10m revenue) and reliant on terminable agencies. Parent cash burn is about A$0.35–0.5m per year, plus investee funding needs (A$1.9m loaned to Cardio), which points to likely further dilution. Governance is concentrated: combined Chair/MD, a three-person board, and related-party share-settled royalty arrangements. There is no analyst coverage and liquidity is thin.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorable
Ongoing (Oct 2026 →)Outcome of the Arna Pharma administration: recapitalisation, sale, or liquidation; any alternative manufacturing or supply arrangement; TGA shortage status updates
MonthlyNTA statements, especially any BTC Pharma valuation change post-Arna
Nov 2026 (expected)AGM and Chairman's address. Expiry of 6m A$0.12 options (23 Nov 2026). Board composition and auditor matters.
Any timeECMO public hospital contract announcements (State tenders)
Any timeNew pharma in-licensing deals to replace Bronchitol/Aridol earnings
Feb 2027 (expected)HY27 results: revenue trajectory, H1 EBITDA (historically weaker), pump stabilisation, Jafron/SmartCanula traction, cash balance
By 30 Jun 2027Related-party royalty settlement election (GLK/Kingfisher/Tau): possible share issuance
Through FY2027Any capital raising; Prescribed List / PBS pricing changes

Concluding analyst verdict

BTC Health has, over three years, rebuilt itself from a write-down-scarred pump distributor into a modest but genuinely diversified ANZ specialty medical-products group. The structural progress is real:

  • cardio has grown to 57% of revenue on the back of the Corcym valve business, PEARS and new cannulas

  • the cost base has been reset to about 41% of sales

  • gross margin is stable at 42.5%

  • the balance sheet is debt-free with 3.14c per share of net tangible assets

  • the second half of FY2026 produced the best EBITDA of the five-year series

However, the investment case remains one of execution under fragility. Headline revenue was flat in FY2026. ECMO conversion keeps slipping on State procurement timing. Pump conversion is slow. Most importantly, the September 2026 administration of Arna Pharma threatens BTC Pharma, the group's highest-earning unit, whose EBITDA exceeded the group's total reported EBITDA in FY2026. Statutory profits are essentially a function of directors' Level 3 valuations, and RSM's Key Audit Matters on valuation and going concern underline that dependence.

At about A$20m market capitalisation (about 1.8x NTA and about 1.8x EV/Sales on group revenue), the market is pricing in a successful cardio scale-up rather than current earnings. Upside depends on three things: ECMO tender wins, Corcym utilisation, and the new SmartCanula, Andocor and Jafron agencies more than offsetting the pharma shortfall while the cost base stays near A$4.2m. Downside comes from a prolonged Bronchitol/Aridol outage, further valuation write-downs, and dilutive funding of investee working capital.

Verdict: BTC Health is a speculative, illiquid micro-cap. The next 6–9 months — the Arna resolution and the HY27 result in February 2027 — are decisive. Until the company demonstrates sustained positive EBITDA without the pharma contribution, the balance of evidence favours a neutral-to-cautious stance, with NTA providing partial but valuation-dependent support.


Data integrity notes

Unaudited figures: All group revenue, gross profit, EBITDA and segment figures are management's unaudited non-statutory numbers.

Derived figures: FY2025 Infusion and Neurospinal segment revenue, FY2025 Corcym and PEARS revenue, half-year H2 figures, and FY2022–FY2023 parent cash are derived values and are flagged where used.

Not disclosed: Employees, geographic split within ANZ, ESG ratings, market share and market sizes are not publicly disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleAppointedTenure (at Oct 2026)AgeQualificationsBackgroundShares heldOptions held

Dr Richard Treagus

Executive Chairman and Managing Director

4 Aug 2014

about 12.2 years

60

BScMed, MBChB, MPharmMed, MBA, MAICD

Physician and entrepreneur with 30+ years in international pharma and biotech; former Director of Neuren Pharmaceuticals Limited

30,000,00016,000,000

Martin Kahanovitz

Non-Executive Director; Chair of Audit & Risk Committee

12 Jun 2025 (AR remuneration note gives 11 Jun 2025)

about 1.3 years

58

Chartered Accountant

CFO of Kahma Healthcare Group; Director of Biovac (The Biologicals and Vaccine Institute of Southern Africa) and Chair of its Finance & Risk Committee; nearly 30 years in biotech, pharma and medical industries

3,850,0000

Felicity McNeill

Non-Executive Director

10 Oct 2022

about 4.0 years

54

BA (Hons), MAICD

25+ years in public and private sectors, including almost 15 years in regulatory and subsidy systems for medicines, vaccines, devices and diagnostics in Australia

00

Executive Leadership Team

NameTitleAppointedPrior roleSharesOptions

Salesh Balak

CFO & Company Secretary

17 Mar 2025

Not disclosed in AR

200,000

3,000,000 (1,000,000 vested)

Joshua Kahanovitz

Chief Operating Officer

17 Mar 2025

Head of Finance (BTC)

42,276,954 (substantial holder, 11.83%)

2,000,000 (all vested)

Oskar Hakansson

Director Commercial Operations / Business Development Director (per data providers)

————

“—” = not publicly disclosed.

Directors' Remuneration

NameSalary and fees (AUD)Annual leave (AUD)Cash bonus (AUD)Long service leave (AUD)Superannuation (AUD)Options (AUD)Total (AUD)

R Treagus

340,000000020,000360,000

M Kahanovitz

35,7140004,286040,000

F McNeill

35,7140004,286040,000

S Balak

245,5364,5930029,46442,092321,685

J Kahanovitz

194,3134,65001,16623,3184,000227,447

Total

851277

9243

0

1166

61354

66092

989132

Directors' Remuneration (Annual)

KMP total (AUD)FY2025FY2026

Total KMP compensation

874,648989,132

Share-Based Incentives

Grant dateExpiryExercise price (AUD)Number

23 Nov 2021

23 Nov 2026

0.1206,000,000

10 Nov 2023

10 Nov 2028

0.04912,000,000

2 Jun 2025

30 Jun 2030

0.0803,000,000

Governance Overview

AttributeStatus

Board size

3

Chair / CEO separation

No. Dr Treagus is Executive Chairman and Managing Director. This is contrary to ASX Corporate Governance Council Recommendation 2.5, which calls for an independent chair.

Independent directors

At most 2 of 3 NEDs. Martin Kahanovitz shares a surname with COO and 11.8% holder Joshua Kahanovitz; no relationship is disclosed in the AR. Readers should check the Governance Statement before treating him as independent.

Committees

Audit & Risk Committee (M Kahanovitz chair; F McNeill). No Remuneration or Nomination Committee.

Meetings FY2026

9 Board meetings (100% attendance); 2 Audit & Risk meetings; 2 circular resolutions

Related-party arrangements

(1) Chairman's fees via PharmaConnect. (2) Royalty agreements with GLK Medical, Kingfisher Medical and Tau Medical Supplies, all associated with COO Joshua Kahanovitz, for products introduced to BTC. Royalties are a percentage of gross profit, payable in BTC shares at 30-day VWAP less 10%. A$187,549 accrued at 30 June 2026 (FY2025 A$92,810); election deferred to 30 June 2027.

Major Shareholders

HolderShares%

NAOS Asset Management

84,996,83723.78

Joshua Kahanovitz (and associates)

42,276,95411.83

Richard Treagus (held via Mrs Karen Elizabeth Treagus)

30,000,0008.39

Visio Fund Management (Pty) Ltd

24,590,1646.88

Major Shareholders by Rank

RankHolderShares%
1

J P Morgan Nominees Australia Pty Limited

97,739,15327.34
2

Mrs Karen Elizabeth Treagus

30,000,0008.39
3

Sigma Company Limited (largest single line; three lines in top 20)

16,856,4674.72
4

HSBC Custody Nominees (Australia) Limited

16,796,1644.70
5

Namarong Investments Pty Ltd

15,000,0004.20

5=

Tau Investments Australia Pty Ltd

14,092,3183.94

5=

Kingfisher Medical Pty Ltd

14,092,3183.94
6

GLK Medical Pty Ltd

14,092,3183.94
7

Citicorp Nominees Pty Limited

12,342,9493.45
8

Mr Thomas Christopher Fennell

8,682,7872.43

Major Shareholders by Ownership Metric

Ownership metricValue

Top 20 holders

82.86%

Holders with more than 100,001 shares

133 holders, 95.96%

Holders with less than a marketable parcel

414

Directors + KMP direct and associated holdings

About 76.4m shares (about 21.4%), incl. J Kahanovitz 42.3m, Treagus 30.0m, M Kahanovitz 3.85m, Balak 0.2m

GLK / Kingfisher / Tau (Kahanovitz-associated per AR Note 17)

42,276,954 shares combined — appears to be the same parcel as the J Kahanovitz substantial holding

Competitive Landscape

Competitors by Segment

SegmentCompetitorTypeOverlap with BTCRelative positioning

Cardio — heart valves

Edwards Lifesciences

Global OEM (direct in ANZ)

Surgical and transcatheter aortic valves vs Corcym/Perceval

Market leader in valves; vastly larger

Cardio — heart valves

Medtronic

Global OEM

Surgical and transcatheter valves, cannulas, ECMO/CPB

Broad portfolio, direct sales force

Cardio — heart valves

Abbott

Global OEM

Mechanical and tissue valves, structural heart

Large, direct

Cardio — ECMO / ECLS

Getinge (Maquet Cardiohelp)

Global OEM

ECMO consoles and oxygenators vs Eurosets

Entrenched ECMO incumbent in Australian ICUs

Cardio — ECMO / CPB / cannulas

LivaNova

Global OEM

Heart-lung machines, oxygenators, cannulas

Strong in perfusion

Cardio — CPB / oxygenators

Terumo Cardiovascular

Global OEM

Oxygenators, CPB circuits

Strong in perfusion

Cardio — hemoperfusion

CytoSorbents; Baxter (oXiris / CRRT)

Global OEMs

Blood purification vs Jafron

CytoSorb is the established sorbent brand

Infusion pumps (pain)

Avanos Medical (ON-Q); Baxter; B. Braun; ICU Medical; Fresenius Kabi

Global OEMs

Elastomeric and electronic ambulatory pumps vs Elasto-Q/Micrel

Broad hospital contracts and bundling

Neuro-spinal / biopsy

Stryker; Medtronic; Merit Medical; Becton Dickinson

Global OEMs

Biopsy needles, navigation markers, bone removal

Large-scale direct sales

Respiratory pharma

Roche (Pulmozyme, dornase alfa); generic hypertonic saline suppliers; methacholine challenge alternatives

Pharma / generics

CF mucoactives vs Bronchitol; bronchial challenge vs Aridol

Competitive pressure explicitly cited for Bronchitol

ANZ distribution peers

Device Technologies Australia (private); Paragon Care / CH2 (ASX-listed; merged with CH2 in 2024); Getz Healthcare; LMT Surgical; Emergo/others

Distributors

Compete for the same overseas OEM agency agreements and hospital accounts

Much larger scale, broader logistics

Peer Comparison FY2026

MetricBTC Health (group)Edwards LifesciencesGetingeLivaNova

Latest revenue

A$10.27m (FY2026, unaudited)

About US$5.4bn (CY2024)

About SEK 35bn (CY2024)

About US$1.25bn (CY2024)

Revenue growth

+0.4% (FY2026)

High single to low double digit (CY2024)

Low to mid single digit (CY2024)

High single digit (CY2024)

Gross margin

42.5%

About 75–80%

About 45–50%

About 65–70%

EBITDA / operating margin

1.3% EBITDA

About 25–30% operating

About 15–20% adj. EBITA

About 15–20% adj. operating

R&D intensity

0%

About 17%

About 5–7%

About 12–13%

Recent Developments

Earlier 2024–early 2025 items are included for context.

Company Snapshot

$6.6M

Revenue

2000

Founded

Hawthorn, Australia

Headquarters

SWOT Analysis

Strengths

  • Cardio franchise scale-up. Cardio revenue rose 31% to A$5.86m (57% of group) in FY2026, from 44% in FY2025 (FY2026 AR).
  • Corcym integration success. Heart-valve revenue grew 91% to A$2.34m in the first full year (FY2026 AR).
  • Debt-free balance sheet. Total liabilities were only A$177,801 against A$11.39m total assets at 30 June 2026 (FY2026 AR).
  • Cost discipline. Group opex fell 2% to A$4.23m (41.1% of sales). Parent expenses fell 37% to A$427,826 (FY2026 AR).
  • Reimbursement access. Micrel and Elasto-Q have been on the Prescribed List since 1 November 2024; Bronchitol is PBS-listed (FY2026 AR; ASX 8 Sep 2026).
  • Anchor public hospital contract. RCH Melbourne ECMO contract worth A$5m over 5 years (HY25 Update).
  • Tax-advantaged PDF structure. Shareholders are exempt on income and gains (FY26 Investor Presentation).
  • Supportive, committed register. NAOS holds 23.78%; insiders hold about 21%. The December 2025 placement drew demand from existing and new institutional and sophisticated investors (FY2026 AR).

Weaknesses

  • Revenue stagnation. Group revenue grew only 0.4% to A$10.27m in FY2026, missing the double-digit target (FY26 Update).
  • Thin profitability. Group EBITDA was A$0.14m (1.3% margin). The first half was loss-making at −A$0.10m (HY26 Update).
  • Statutory earnings are valuation-driven. The FY2023 loss of A$10.17m came from a A$9.62m write-down; FY2025 profit of A$3.98m came from a A$4.65m fair-value gain (FY2026 AR 5-year table).
  • Persistent parent cash burn. Operating cash outflow has run at A$0.35–0.50m per year for five years, plus A$1.70m of investee loans across FY2025–FY2026 (FY2026 AR).
  • Infusion pump erosion. Pump revenue fell 35% to A$1.92m, and Speciality Health's valuation was cut by A$1.28m (FY2026 AR).
  • Governance concentration. The roles of Chair and MD are combined. The board has three directors and no remuneration or nomination committee. Related-party royalty agreements exist with entities associated with the COO (FY2026 AR).
  • Limited disclosure. No audited consolidated accounts, no headcount, and no segment balance sheets.

Opportunities

  • ECMO pipeline conversion. Evaluations are "well advanced across most major public hospitals". Even reverting to FY2025's A$2.29m from FY2026's A$1.60m adds about A$0.7m of revenue (FY26 Update).
  • New FY2026 agencies ramping. SmartCanula, Andocor and Jafron sell to existing customers and were not yet material to FY2026 (FY2026 AR).
  • Perceval Plus utilisation in established centres; HY25 guidance implied about A$3.6m annualised Corcym potential versus A$2.34m achieved (HY25 Update).
  • Pump recovery as ambIT users convert to reimbursed Micrel/Elasto-Q (FY2026 AR).
  • Operating leverage. With opex at 41% of sales and gross margin at 42.5%, incremental revenue at constant margin flows largely to EBITDA (analyst calculation from FY2026 AR).
  • New pharma in-licensing. This is an explicit FY27 priority, made urgent by the Arna situation (FY2026 AR).
  • Tax losses. A$30.1m of unrecognised tax losses could shelter future taxable income, subject to PDF rules (FY2026 AR Note 4).

Threats

  • Arna Pharma insolvency. Bronchitol/Aridol FY2027 sales are guided to fall to at most A$0.5m from A$1.1m. BTC Pharma was the most profitable investee (A$0.36m EBITDA) (ASX 8 Sep 2026; FY2026 AR).
  • TGA anticipated shortages. Aridol from 1 October 2026 and Bronchitol from 1 April 2027 (TGA database).
  • Public hospital procurement delays depressing ECMO revenue (FY2026 AR).
  • Agency termination or OEMs moving to direct distribution (AR risk factor: "Dependence on product supply agreements").
  • Government pricing reform for the Prescribed List and PBS (AR risk factor).
  • Valuation downside and impairment risk. The disclosed sensitivity for BTC Pharma (a 5% revenue decline gives a −A$2.2m fair-value impact) suggests the A$1.53m carrying value is highly exposed to the Arna event (FY2026 AR Note 19).
  • Equity dilution if further working-capital funding is required. Going concern was a Key Audit Matter for FY2026 (RSM audit report).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Nov 2024Micrel and Elasto-Q listed on the Prescribed List of Medical DevicesEnabled reimbursement-driven conversion from ambIT
Dec 2024BTC Cardio enters exclusive partnership with CorcymTransformational; cardio becomes the largest segment
10 Feb 2025Arna Pharma partnership expanded (indefinite licence, ROFR)Lengthened pharma licence life (now undermined)
12 Feb 2025CFO and Company Secretary appointment announcedFinance function upgrade
24 Feb 2025HY25 results: statutory profit A$4.9m; group revenue +9% to A$5.3m; group EBITDA A$0.26mPeak half-year EBITDA before FY2025 H2 reversal
17 Mar 2025S Balak (CFO/CoSec) and J Kahanovitz (COO) commenceLeadership restructure
2 Jun 20253m options granted to CFO (A$0.08 exercise)Executive retention
11–12 Jun 2025B York resigns; M Kahanovitz appointed NEDBoard change
Mid-2025Insider buying signal
27 Jun 2025Change in substantial holding lodgedRegister movement (NAOS/other)
1 Jul 2025Notification regarding unquoted securitiesOption administration
22 Jul 2025BTC wins A$0.5m ECMO equipment order (Adelaide WCH, installed Jul 2025)ECMO pipeline conversion
Aug 2025Short-term insurance premium funding facility of A$141,348 drawn (later repaid)Minor liquidity management
28 Aug 2025FY2025 results: statutory profit A$3.98m; group revenue A$10.23m; group EBITDA A$3kRevenue step-up; EBITDA only break-even
28 Nov 2025A$2.0m placement announced; AGM; Chairman's address targets year-on-year revenue growth; RSM appointed auditorBalance-sheet repair; governance
2 Dec 202532.13m shares issued at 6.1c (about 9.9% dilution)Cash to A$2.08m (group) by June 2026
3 Dec 2025Re-issued Chairman's AGM addressDisclosure correction
13 Feb 2026Exclusive ANZ distribution of Jafron hemoperfusion productsNew critical-care adjunct line
19 Feb 2026HY26 results: group revenue −7% to A$4.98m; EBITDA −A$0.10m; statutory loss A$86,975; cardio 53% of revenueECMO timing slippage disclosed
Mar–Jul 2026Monthly NTA statements show investee valuations re-weighted. Pharma fell from A$2.14m (Mar) to A$1.53m (Jun); Speciality Health rose from A$2.33m to A$3.00m; Cardio rose from A$3.24m to A$3.46m.Year-end valuation reset
13 Jul 2026NTA at 30 June 2026 releasedNTA 3.14c per share
20 Aug 2026FY2026 results: revenue A$10.27m; EBITDA A$0.14m; adjusted A$0.27m; statutory profit A$34,728; cardio 57%Return to positive full-year EBITDA; growth target missed
20 Aug 2026Three new FY2026 distribution agreements confirmed (SmartCanula, Andocor, Jafron)Pipeline for FY2027
20 Aug 2026Appendix 4G / Corporate Governance Statement lodgedGovernance disclosure
17 Aug 2026NTA at 31 July 2026 released (investee values unchanged from June)—
7–8 Sep 2026Arna Pharma enters voluntary administration. BTC holds about 8 months of Bronchitol and less than 1 month of Aridol stock. FY2027 pharma sales guided to at most A$0.5m without supply.Material adverse event for most profitable investee
Sep–Oct 2026TGA lists anticipated shortages: Aridol (1 Oct 2026 – 31 Dec 2027), Bronchitol (1 Apr 2027 – 31 Dec 2027); reason "commercial changes / commercial viability"Confirms supply-disruption risk publicly

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Revenue by Segment (FY2024–FY2026): Group total revenue rose from AUD 8.2 Mn in FY2024 to AUD 10.3 Mn in FY2026.
BTC Health Limited — Revenue by Segment (FY2024–FY2026)
Series (AUD Mn)FY2024FY2025FY2026
Group total revenue8.210.210.3
Cardio revenue—4.55.9
Infusion Pumps revenue—31.9
Neurospinal revenue—1.51.4
Pharma revenue—1.31.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.